| Autor: |
Kirsty Hodgson, Margarita Orozco-Moreno, Emily Archer Goode, Matthew Fisher, Rebecca Garnham, Richard Beatson, Helen Turner, Karen Livermore, Yuhan Zhou, Laura Wilson, Eline A. Visser, Johan FA. Pijnenborg, Nienke Eerden, Sam J. Moons, Emiel Rossing, Gerald Hysenaj, Rashi Krishna, Ziqian Peng, Kyla Putri Nangkana, Edward N. Schmidt, Adam Duxfield, Ella P. Dennis, Rakesh Heer, Michelle A. Lawson, Matthew Macauley, David J. Elliott, Christian Büll, Emma Scott, Thomas J. Boltje, Richard R. Drake, Ning Wang, Jennifer Munkley |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
EBioMedicine, Vol 104, Iss , Pp 105163- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2352-3964 |
| DOI: |
10.1016/j.ebiom.2024.105163 |
| Popis: |
Summary: Background: Bone metastasis is a common consequence of advanced prostate cancer. Bisphosphonates can be used to manage symptoms, but there are currently no curative treatments available. Altered tumour cell glycosylation is a hallmark of cancer and is an important driver of a malignant phenotype. In prostate cancer, the sialyltransferase ST6GAL1 is upregulated, and studies show ST6GAL1-mediated aberrant sialylation of N-glycans promotes prostate tumour growth and disease progression. Methods: Here, we monitor ST6GAL1 in tumour and serum samples from men with aggressive prostate cancer and using in vitro and in vivo models we investigate the role of ST6GAL1 in prostate cancer bone metastasis. Findings: ST6GAL1 is upregulated in patients with prostate cancer with tumours that have spread to the bone and can promote prostate cancer bone metastasis in vivo. The mechanisms involved are multi-faceted and involve modification of the pre-metastatic niche towards bone resorption to promote the vicious cycle, promoting the development of M2 like macrophages, and the regulation of immunosuppressive sialoglycans. Furthermore, using syngeneic mouse models, we show that inhibiting sialylation can block the spread of prostate tumours to bone. Interpretation: Our study identifies an important role for ST6GAL1 and α2-6 sialylated N-glycans in prostate cancer bone metastasis, provides proof-of-concept data to show that inhibiting sialylation can suppress the spread of prostate tumours to bone, and highlights sialic acid blockade as an exciting new strategy to develop new therapies for patients with advanced prostate cancer. Funding: Prostate Cancer Research and the Mark Foundation For Cancer Research, the Medical Research Council and Prostate Cancer UK. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
